Resumen de acción MOVE
Medacta Group SA desarrolla, fabrica y distribuye dispositivos médicos ortopédicos y neuroquirúrgicos Europa, Norteamérica, Asia-Pacífico y a escala internacional.
| Puntuación del snowflake | |
|---|---|
| Valoración | 2/6 |
| Crecimiento futuro | 3/6 |
| Rendimiento pasado | 3/6 |
| Salud financiera | 5/6 |
| Dividendos | 0/6 |
Competidores de Medacta Group SA
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | CHF 113.60 |
| Máximo en las últimas 52 semanas | CHF 135.00 |
| Mínimo de 52 semanas | CHF 107.80 |
| Beta | 1.14 |
| 1Cambio en 1 mes | -8.83% |
| Variación en 3 meses | -7.49% |
| Cambio de 1 año | 0.53% |
| 3Variación en 3 años | -30.82% |
| Variación en 5 años | 39.39% |
| Variación desde la OPV | 18.21% |
Noticias y actualizaciones recientes
Is Medacta Group (VTX:MOVE) A Risky Investment?
Oct 14
Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate
Sep 06What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?
Aug 21Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return
Aug 06Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable
Jun 20Recent updates
Is Medacta Group (VTX:MOVE) A Risky Investment?
Oct 14Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate
Sep 06What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?
Aug 21Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return
Aug 06Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable
Jun 20We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
May 01Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet
Apr 17Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?
Mar 29Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?
Feb 22Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around
Feb 07Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult
Dec 18Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)
Dec 04Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?
Nov 15Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)
Oct 30If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity
Oct 17Is Medacta Group (VTX:MOVE) Using Too Much Debt?
Sep 29Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)
Aug 11Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?
Jul 27Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital
Jul 03At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?
Apr 28Is Medacta Group (VTX:MOVE) A Risky Investment?
Apr 08Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?
Dec 25Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal
Dec 09Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?
Nov 09Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching
Sep 16The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence
Aug 20Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors
Jul 02Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?
May 28Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return
May 12These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well
Mar 31Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?
Mar 17Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future
Feb 07Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?
Dec 10Medacta Group (VTX:MOVE) Knows How To Allocate Capital
Nov 05Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly
Sep 30Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?
Aug 26Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital
Jul 20Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?
May 19We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt
Apr 05What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition
Mar 02Is Medacta Group SA's (VTX:MOVE) 7.6% ROE Better Than Average?
Feb 02The Medacta Group (VTX:MOVE) Share Price Has Gained 24% And Shareholders Are Hoping For More
Jan 12
Returns On Capital At Medacta Group (VTX:MOVE) Paint An Interesting Picture
Dec 21Should You Use Medacta Group's (VTX:MOVE) Statutory Earnings To Analyse It?
Dec 03Rentabilidad de los accionistas
| MOVE | CH Medical Equipment | Mercado CH | |
|---|---|---|---|
| 7D | -1.9% | -4.4% | -2.2% |
| 1Y | 0.5% | 19.7% | 11.2% |
Rentabilidad vs. Industria: MOVE underperformed the Swiss Medical Equipment industry which returned 19.7% over the past year.
Rentabilidad vs. Mercado: MOVE underperformed the Swiss Market which returned 11.2% over the past year.
Volatilidad de los precios
| MOVE volatility | |
|---|---|
| MOVE Average Weekly Movement | 3.8% |
| Medical Equipment Industry Average Movement | 3.9% |
| Market Average Movement | 3.2% |
| 10% most volatile stocks in CH Market | 7.1% |
| 10% least volatile stocks in CH Market | 1.6% |
Precio estable de las acciones: MOVE has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatilidad a lo largo del tiempo: MOVE's weekly volatility (4%) has been stable over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1958 | 1,826 | Francesco Siccardi | www.medacta.com |
Medacta Group SA desarrolla, fabrica y distribuye dispositivos médicos ortopédicos y neuroquirúrgicos en Europa, Norteamérica, Asia-Pacífico e internacionalmente. Ofrece herramientas personalizadas de planificación en 3D para su uso en procedimientos de cadera, rodilla, hombro, sustitución articular, medicina deportiva y columna vertebral. Medacta Group SA se fundó en 1958 y tiene su sede en Castel San Pietro, Suiza.
Resumen de fundamentos de Medacta Group SA
| Estadísticas fundamentales de MOVE | |
|---|---|
| Capitalización bursátil | CHF 2.27b |
| Beneficios(TTM) | CHF 52.88m |
| Ingresos (TTM) | CHF 512.02m |
42.9x
Ratio precio-beneficio (PE)4.4x
Ratio precio-ventas (PS)¿Está MOVE sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de MOVE | |
|---|---|
| Ingresos | €544.29m |
| Coste de los ingresos | €174.57m |
| Beneficio bruto | €369.72m |
| Otros gastos | €313.51m |
| Beneficios | €56.21m |
Últimos beneficios comunicados
Jun 30, 2024
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 2.82 |
| Margen bruto | 67.93% |
| Margen de beneficio neto | 10.33% |
| Ratio deuda/patrimonio | 54.1% |
¿Cómo se ha desempeñado MOVE a largo plazo?
Ver rendimiento histórico y comparativa